Pasar al contenido principal

SINTESIS DE ACTIVADORES DE AMPK: UNA QUINASA RELEVANTE EN PROCESOS METABOLICOS Y DE SUPERVIVENCIA NEURONAL

CTQ2010-19690

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2010
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

  • Bort Bueno, Alicia
  • Quesada Sánchez, Sergio
  • Ramos-Torres, Ágata
  • Gargantilla, Marta
  • Priego, Eva María
  • Raynal, S.
  • Lepifre, F.
  • Gasalla, José María
  • Rodriguez-Henche, Nieves
  • Castro Morera, Ana
  • Díaz-Laviada, Inés
The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of α1 or α2 isoforms as well as in vitro assays using human recombinant α1β1γ1 or α2β1γ1 AMPK isoforms revealed that compound 8c exhibit preference for AMPKα1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer., The authors would like to thank the Spanish Ministry of Economy and Competitiveness (Grant n° BFU2012- 31444; CTQ2010-19690); Junta de Comunidades Castilla-LaMancha and Fondo Europeo de Desarrollo Regional (FEDER) (Grant n° POII11-0159-0054); Comunidad de Madrid (Grant S2010-BMD2308); and the Fundación Tatiana Pérez de Guzmán el Bueno (Grant n° Patrocinio 2013-001) for financial support into their research. S.Q. is the recipient of a fellowship (Grant JAE-Pre-2011) from Junta para la Ampliación de Estudios cofinanced by Fondo Socio Europeo (FSE)., Peer reviewed, Peer Reviewed
e_Buah Biblioteca Digital Universidad de Alcalá
Publicación Artículo científico (JournalArticle)

Identification of a novel 2-oxindole fluorinated derivative as in vivo antitumor agent for prostate cancer acting via AMPK activation

  • Bort Bueno, Alicia Carmen|||0000-0003-1490-5823
  • Quesada Sánchez, Sergio
  • Ramos Torres, Ágata
  • Gargantilla López, Marta
  • Priego, Eva Maria
  • Raynal, Sophie
  • Lepifre, Franck
  • Gasalla Herráiz, José Manuel
  • Rodríguez Henche, María de las Nieves|||0000-0001-9798-359X
  • Castro Morera, Ana
  • Díaz-Laviada Marturet, Inés Cecilia|||0000-0001-9704-4373
The key metabolic sensor adenosine monophosphate-dependent kinase (AMPK) has emerged as a promising therapeutic target for cancer prevention and treatment. Besides its role in energy homeostasis, AMPK blocks cell cycle, regulates autophagy and suppresses the anabolic processes required for rapid cell growth. AMPK is especially relevant in prostate cancer in which activation of lipogenic pathways correlate with tumor progression and aggressiveness. This study reports the discovery of a new series of 2-oxindole derivatives whose AMPK modulatory ability, as well as the antitumoral profile in prostate cancer cells, was evaluated. One of the assayed compounds, compound 8c, notably activated AMPK in cultured PC-3, DU145 and LNCaP prostate cancer cells. Likewise, compound 8c caused PC-3, DU145 and LNCaP cells viability inhibition. Selective knocking down of ?1 or ?2 isoforms as well as in vitro assays using human recombinant ?1?1?1 or ?2?1?1 AMPK isoforms revealed that compound 8c exhibit preference for AMPK?1. Consistent with efficacy at the cellular level, compound 8c was potent in suppressing the growth of PC-3 xenograft tumors. In conclusion, our results show that a new 2-oxindole fluorinated derivative exerts potent in vivo antitumor actions against prostate cancer cells, indicating a promising clinical therapeutic strategy for the treatment of androgen-independent prostate cancer., Ministerio de Economía y Competitividad, Junta de Comunidades de Castilla-La Mancha, Fondo Europeo de Desarrollo Regional, Comunidad Autónoma de Madrid, Fundación Tatiana Pérez de Guzmán el Bueno, Junta para la Ampliacion de Estudios